《大行》野村升威高股份(01066.HK)目標價至7.08元 料中期盈利增8%
野村發表研究報告指,預計威高股份(01066.HK)上半年銷售按年升6.2%至70.5億元人民幣(下同),並料盈利增8%至12億元,又預計醫藥包裝和骨科產品領域的高增長將抵銷其他醫療耗材的較弱表現。該行預期公司上半年利潤率穩定,料毛利率及經營溢利率分別爲51%和19.6%。
展望下半年,該行預期威高股份在去年同期相對較低的基數下,收入及盈利料按年增長15.8%和19.3%,分別爲75億元及11億元。
以現金流折現率計,該行將公司目標價由6.29港元上調至7.08港元,評級爲「買入」。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.